Too Costly to Defend: Who Is Benefited From the U.S. Supreme Court’s Recent Holdings Concerning Biotechnology Patent Disputes?
18.0000000000000 ALB. L.J. SCI. & TECH. 53 (2008)
Yi-Chen Su, Albert Wai-Kit Chan
Justice Scalia’s recent holdings on behalf of the Supreme Court in Merck KGaA v. Integra Lifesciences I, Ltd. and MedImmune Inc. v. Genentech, Inc. have had a grave impact on biotechnology research. These cases represent the two sides of the same coin and, therefore, should be examined together rather than separately.